Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus.
Suzuki Y, Kaneko H, Okada A, Itoh H, Matsuoka S, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Kamiya K, Matsunaga A, Ako J, Node K, Yasunaga H, Komuro I.
Suzuki Y, et al. Among authors: node k.
Cardiovasc Diabetol. 2022 May 18;21(1):67. doi: 10.1186/s12933-022-01508-6.
Cardiovasc Diabetol. 2022.
PMID: 35585590
Free PMC article.